Lifeline Therapeutics (fka LFLT)

[Steeley]

Lifeline Therapeutics Launches Protandim, A First-of-its-Kind Antioxidant Therapy
First Antioxidant Therapy Proven to Eliminate Age-Related Oxidative Stress, Featured on ABC Primetime Live

Lifeline Therapeutics, Inc. (OTCBB:LFLT), dedicated to developing products that help people live better, healthier and longer lives by fighting oxidative damage in the body, today announced Protandim -- a first-of-its-kind, patent-pending antioxidant therapy that turns "on" the body's catalytic system to naturally produce key antioxidants inside the cell, where they are needed most. Unlike other antioxidants that require high doses and are not absorbed well within the body, Protandim is the first dietary supplement proven to restore age-related oxidative stress to levels seen in someone 20 years old or younger by increasing the body's own catalytic antioxidant defense and repair system. Protandim was positively featured on ABC Primetime Live on June 2.

"Everyone is looking for ways to manage the effects of aging and extend their youth," said Bill Driscoll, president and CEO of Lifeline Therapeutics. "Unfortunately, most products currently on the market are ineffective and unsubstantiated. With Protandim there is now a scientifically based antioxidant therapy that induces the production of the body's own natural antioxidants and extends one's healthy life expectancy."

The announcement of Protandim comes on the heels of a recent U.S. scientific study on aging, led by Dr. Peter Rabinovitch and his colleagues at the University of Washington School of Medicine. They found that increasing the amount of antioxidants naturally produced in the body, such as Catalase (CAT), can dramatically slow the aging process, destroy free radicals and promote healthier life. The study prolonged the lives of laboratory mice by 20 percent using a technique that boosts their natural antioxidant defenses. In addition to increased life expectancy, the mice had healthier heart muscle tissue, indicating that CAT helped protect them from age-related heart problems. The study indicates that stimulating the body's own production of natural antioxidants, such as the way Protandim revs up the body's natural antioxidant defenses, is the best approach to combating oxidative stress and the aging process itself.

A New Approach to Oxidative Stress

Oxidative stress is the harmful condition that occurs when there are excessive free radicals or a marked decrease in antioxidant levels, causing the body to age -- similar to how a car rusts or an apple turns brown. It has been scientifically demonstrated that high levels of oxidative stress negatively impact the body's healthy life expectancy. Particularly in the United States and Western world, the last ten years of life tend to be plagued by various degenerative health issues and illnesses often associated with oxidative stress.

Protandim offers a new, proven approach to fight oxidative stress -- the ability to increase the body's levels of two essential natural antioxidant enzymes: Superoxide Dismutase (SOD) and Catalase (CAT). Unfortunately, the body's production of these natural antioxidant enzymes declines with age, allowing for a plethora of age-related concerns to have an upper hand in the conditions we associate with aging.

Traditional antioxidant supplements, like Vitamin C and E, are "consumable" antioxidants. They are taken to fight oxidants and the resulting damage, which is oxidative stress. They fight oxidants on a 1-to-1 level and are then consumed or used up and flushed out of the system. Protandim is a fundamentally different approach. Like a catalytic converter in a car, Protandim induces the body to increase the production of its own natural catalytic antioxidant defense system and thus provides highly efficient antioxidant protection. The botanical ingredients in Protandim induce the cells to produce more of their own antioxidant catalysts. Rather than eliminating oxidants 1-for-1, these catalysts are tens of thousands of times more effective because they destroy oxidants without being consumed or used up themselves. Combined, they can eliminate up to one million oxidants per second.

Backed by Science

Protandim is co-formulated by Dr. Joe McCord, the co-discoverer of SOD in 1969. Dr. McCord is Director of Science for Lifeline Therapeutics, the developer and distributor of Protandim. In 1997, Dr. McCord was awarded the prestigious Elliot Cresson Medal from The Franklin Institute for "his seminal work of discovering and elucidating the biology of free radical reactions and their enzymatic controls in living organisms, as well as the pathology of free radical diseases." Through its awards program, The Franklin Institute seeks to provide public recognition and encouragement of excellence in science and technology. The list of Franklin Institute laureates reads like a "Who's Who" in the history of 19th and 20th century science, including Alexander Graham Bell, Pierre and Marie Curie, Rudolf Diesel, Thomas Edison, Niels Bohr, Max Planck, Albert Einstein and Stephen Hawking. To date, 101 Franklin Institute laureates also have been honored with 103 Nobel Prizes. Dr. McCord received a Lifetime Achievement Award from the Society for Free Radical Biology and Medicine for outstanding contributions to the field. Dr. McCord serves as President of the International Society of Antioxidants in Nutrition and Health (ISANH).

"Throughout my entire career, I've been focused on antioxidants. Protandim is unlike other antioxidants or supplements available because it works within the cells to optimize the body's natural enzymes," said Dr. Joe McCord. "The pre-clinical and clinical studies have clearly demonstrated the effectiveness and impact of Protandim. In fact, in clinical studies, Protandim restored oxidative stress to the level of someone younger than 20 years old."

Lifeline Therapeutics has completed pre-clinical trials and clinical trials with the University of Colorado Health Sciences Center. In clinical studies, participants were evaluated at 0, 30, and 120 days with blood tests measuring oxidative stress via TBARS, as well as levels of the body's natural enzymes, Superoxide Dismutase (SOD) and Catalase (CAT). Initial data from the pre-clinical and clinical studies have substantiated that Protandim can significantly reduce oxidative stress and effectively eliminate age-related oxidative stress.

Product Availability

Protandim is available online at www.Protandim.com and by calling 1-8-PROTANDIM (1-877-682-6346). A 30-day supply can be purchased for $49.95.

About Lifeline Therapeutics

Lifeline Therapeutics, Inc. is a publicly traded company (OTCBB:LFLT) based in Denver, Colorado, that is dedicated to developing and marketing evidenced-based pharmaceutical products that show advanced efficacy in dealing with oxidative-stress related diseases -- including cancer and diabetes -- as well as nutraceutical and cosmeceutical products that demonstrate vastly superior antioxidant protection and anti-aging results. The Company's scientific platform is based on breakthrough research involving the body's natural antioxidant enzymes, Superoxide Dismutase (SOD) and Catalase (CAT). These enzymes are thousands of times more powerful than consumable antioxidants and can increase "Healthy Life Expectancy" through the avoidance or diminishing of age-related disease conditions. Lifeline has developed a patent-pending composition, Protandim, that has been proven to be the first and only dietary supplement to simultaneously increase these two enzymes and reduce oxidative stress levels to those of a 20-year-old or younger. To underscore the Company's commitment to higher quality of life and healthy life expectancy, Lifeline Therapeutics has pledged 10% of its pre-tax profits to support orphanages and other global humanitarian needs. For more information, visit www.Protandim.com.

Except for historical information contained herein, this document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and applicable common law. These statements involve known and unknown risks and uncertainties that may cause the Company's actual results or outcomes to be materially different from those anticipated and discussed herein. Further, the Company operates in industries where securities values may be volatile and may be influenced by regulatory and other factors beyond the Company's control. Other important factors that the Company believes might cause such differences include the Company's limited cash flow and the rapid development of technology, lack of liquidity for the Company's common stock, working capital shortages, the length of time for scientific advances to reach the market (if they ever reach the market), among other risks. In assessing forward-looking statements contained herein, readers are urged to carefully read all cautionary statements contained in the Company's filings with the Securities and Exchange Commission.

CONTACT:
Ogilvy Public Relations Worldwide Aliza Rothman, 303-634-2672 [e-mail]

http://www.genengnews.com/news/bnitem.aspx?name=543085XSL_NEWSML_TO_NEWSML_WEB.xml